<SEC-DOCUMENT>0001753926-23-001180.txt : 20240314
<SEC-HEADER>0001753926-23-001180.hdr.sgml : 20240314
<ACCEPTANCE-DATETIME>20230901170618
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001753926-23-001180
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230901

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chromocell Therapeutics Corp
		CENTRAL INDEX KEY:			0001919246
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				863335449
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		685 US HIGHWAY ONE
		CITY:			NORTH BRUNSWICK
		STATE:			NJ
		ZIP:			08902
		BUSINESS PHONE:		9176446313

	MAIL ADDRESS:	
		STREET 1:		685 US HIGHWAY ONE
		CITY:			NORTH BRUNSWICK
		STATE:			NJ
		ZIP:			08902
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 37px; width: 243px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chromocell Therapeutics Corporation<BR>
4400 Route 9 South, Suite 1000<BR>
Freehold, NJ 07728</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 1, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Via EDGAR</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Doris Stacey Gama and Jason Drory</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">100 F Street, NE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Chromocell Therapeutics Corporation<BR>
    Amendment No. 3 to Registration Statement on Form S-1 </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Filed June 30, 2023</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>File No. 333-269188</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Madam and Sir:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This correspondence responds
to the letter, dated July 10, 2023, received from the staff of the Securities and Exchange Commission (the &ldquo;Staff&rdquo;) regarding
the abovementioned Amendment No. 3 to Registration Statement on Form S-1 filed on June 30, 2023 by Chromocell Therapeutics Corporation
(the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; or &ldquo;our&rdquo;). For convenience, the Staff&rsquo;s comments are
restated below in bold text, with each comment followed by our response. We are concurrently filing with this letter Amendment No. 5 to
Registration Statement on Form S-1 (&ldquo;Amendment No. 5&rdquo;). Capitalized terms used, but not defined, in this letter have the meanings
ascribed to such terms in Amendment No. 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Amendment No. 3 to Registration Statement
on Form S-1 filed June 30, 2023</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recent Developments, page 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>We note the liquidation preference on your Series B preferred stock. Please include a summary risk factor disclosure, and a full risk factor, addressing the material risks to your common stockholders associated with the liquidation preference on the preferred stock, including that the liquidation preference could have the effect of preventing your common stockholders from receiving any proceeds in the event your company is liquidated. In addition, please revise your risk factors and similar statements throughout your filing to acknowledge that your Series B preferred stock is entitled to an 10% annual dividend.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Response: In response to the Staff&rsquo;s
comment, we have revised the disclosure regarding Series B Preferred Stock throughout Amendment No. 5 accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
or require additional information, please contact the Company&rsquo;s counsel, David E. Danovitch at (212) 660-3060 or at ddanovitch@sullivanlaw.com
or Aaron M. Schleicher at (212) 660-3034 or at aschleicher@sullivanlaw.com, of Sullivan &amp; Worcester LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD>
    <TD STYLE="width: 63%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chromocell Therapeutics Corporation </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/ Francis Knuettel II</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Francis Knuettel II</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Interim Chief Executive Officer and Chief Financial Officer </FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="width: 99%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;Kristin Lochhead and Daniel Gordon, Securities and Exchange Commission</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;David E. Danovitch, Esq., Sullivan &amp; Worcester LLP </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;Aaron M. Schleicher, Esq., Sullivan &amp; Worcester LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  N 3 # 2(  A$! Q$!_\0
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M,>?Y$4 >Q6?Q$T74M9M--T]Y;B6X8C<$PJX!/)/TKGOC1_R"M,_Z[M_*N?\
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M?PUU2ZU:\N$N[()+.[J"7R 2>O%>@_#_ $2?P_X=-G<R122><S[H\XP<>HH
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5Z5Y5_P *NU;_ )_+'\W_ ,* 1__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
